Skip to main content

Advertisement

Table 1 Patient characteristics, toxicities, and response to therapy

From: Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

Patient code Age Sex Stage Disease sites Prior therapy Tremelimumab doses, no. Treatment-related toxicity, G2/G3 Best response
1103 80 M IVc Liver   2 Diarrhea G2 PD
     Lung     
1104 63 M IVb LN Temozolomide, thalidomide, IL-2 2   PD
     Lung     
     Liver     
     Adrenal     
     Kidney     
1105A 61 M IVc LN Cisplatin, vinblastine, temozolomide, IL-2, IFN, lenalidomide, MART1/DC 11 Hepatitis G3 Acne Rosacea G2 SD × 11 mos
     Lung     
     Stomach     
1105P 55 F IVc LN Cisplatin, vinblastine, dacarbazine, paclitaxel, gefitinib, BCG, IL-2, IFN 4   PD
     Lung     
     Liver     
1106 52 F IVc LN Cisplatin, vinblastine, dacarbazine 4 Diarrhea G3 Rash G2 PD
     Lung     
     Liver     
1107 57 M IVc LN Heat shock 2   PD
     Liver Protein    
1108 55 F IIIc SC GM-CSF 5 Hepatitis G3 Hypophysitis G2 CR × 39+ mo.
     LN     
1109 54 M IVa LN ILX 651 3 Leuko-cytoclastic vasculitis G3 PD
1110 34 M IVa SC IL-2 3   PD
     LN     
1111 90 M IIIc Skin BCG, 8 Diarrhea G2 PR × 34+ mo.
     LN AMG 706    
1113 63 M IVa LN IFN 22 Hypophysitis G2 Elevated trans-aminases G2 Asthenia G2 Arthralgia G2 Grover's G2 Uveitis G2 pPR × 33+ mo.
1114 61 M IVa LN IFN, temozolomide 2 Colitis G3 SD × 8 mo.
  1. No. = Number; G = Grade; M = Male; PD = Progressive disease; LN = Lymph node; IL-2 = Interleukin-2; SD = Stable disease; mo.= Months; IFN = Interferon; MART1 = Melanoma-associated antigen recognized by T cells; DC = Dendritic cells; F = Female; BCG = Bacillus Calmette-Guérin; SC = Subcutaneous; GM-CSF = Granulocyte-macrophage colony-stimulating factor; CR = Complete response; PR = Partial response; pPR = Pathological partial response.